Black patients experience health-care disparities in the early diagnosis and treatment of Lyme disease, according to a new study published by Starke et al in JAMA Network Open. In a cross-sectional study, investigators examined the data of 1,395 patients with suspected untreated or posttreatment Lyme disease. They then divided the patients into three groups on the basis of their Lyme disease presentations: those with erythema migrans rash without evidence of disseminated disease; those with evidence of disseminated neurologic, cardiac, or joint disease without considering prior erythema migrans; and those with patient-reported, suspected symptoms of Lyme disease without objective evidence. Last, they examined rates of disseminated disease and objective evidence by race. Black patients were 4.93 times more likely to have disseminated Lyme disease (95% confidence interval [CI] = 2.02–12.02) compared with patients who only had erythema migrans rash. Additionally, Black patients (odds ratio [OR] = 2.05, 95% CI = 1.12–3.84), female patients (OR = 1.39, 95% CI = 1.09–1.77), and younger patients (OR = 1.12, 95% CI = 1.04–1.20) independently had higher risks of being categorized into the group with patient-reported symptoms only. The investigators also revealed that Black patients had a longer median time to treatment with antibiotics compared with White patients (35 vs 7 days)—especially among those with erythema migrans rash only. The investigators concluded that their new findings illuminated a critical need to address gaps in health-care access, racial discrimination, and implicit bias in Lyme disease diagnosis and treatment among Black patients.